Research News
View articles by month and year
-
About 25% of Women Either Don’t Start or Don’t Finish Hormonal Therapy
A study suggests that about 25% of women who are prescribed hormonal therapy to reduce the risk of recurrence after surgery either don’t start taking the medicine or stop taking it early.
-
Femara Better Than Tamoxifen for Certain Types of Breast Cancer
Femara was better than tamoxifen in treating postmenopausal women diagnosed with estrogen-receptor-positive, HER2-negative, lobular breast cancer; it was also better at treating luminal B breast cancers.
-
Ten Years of Tamoxifen Better Than Five for Early-Stage, Estrogen-Receptor-Positive Disease
For women diagnosed with early-stage, estrogen-receptor-positive breast cancer, 10 years of tamoxifen offers more benefits than 5 years.
-
Aromatase Inhibitors Seem Less Effective in Obese Women
A small study found that while obese women diagnosed with early-stage, hormone-receptor-positive breast cancer who took Arimidex and Femara had lower estrogen levels than before they started treatment, their estrogen levels were still more than double those of women at a healthy weight.
-
Fracture Risk in Younger Women Being Treated for Breast Cancer Higher Than Thought
A study found that about 16% of premenopausal women treated for early-stage breast cancer broke a bone during treatment or in the years after treatment; this rate was 60% higher than expected.
-
Femara Offers More Benefits Than Tamoxifen After Breast Cancer Surgery
New results boost evidence that postmenopausal women get more benefits from 5 years of Femara compared to 5 years of tamoxifen after surgery for early-stage, hormone-receptor-positive breast cancer.
-
Prolia Approved by FDA to Treat Bone Loss in Women Taking Aromatase Inhibitor
The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors.
-
Most Women with Early-Stage Breast Cancer Benefit from Treatments After Surgery
Research suggests that that most women diagnosed with early-stage breast cancer are likely to benefit from chemotherapy, hormonal therapy, and/or targeted therapy after surgery.
-
Is Switching Hormonal Therapies Better Than Taking Only One?
Research suggests that taking tamoxifen for 2 to 3 years and then switching to an aromatase inhibitor might be better than taking only tamoxifen or only an aromatase inhibitor for 5 years to reduce recurrence risk and improve overall survival.
-
Tamoxifen Reduces Recurrence Risk for More Than 10 Years
Research has confirmed that tamoxifen reduces breast cancer recurrence risk during the standard 5 years of treatment and that recurrence risk stays lower during the next 5 years after tamoxifen treatment ends.
